# Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280

> **NCT00681746** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 8 (estimated)

## Conditions studied

- Anxiety

## Interventions

- **DRUG:** AZD6280
- **DRUG:** (11C) flumazenil

## Key facts

- **NCT ID:** NCT00681746
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2010-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681746, "Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00681746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*